RT Journal Article
SR Electronic
T1 Validate Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.10.21258706
DO 10.1101/2021.06.10.21258706
A1 Qian Li
A1 Hansi Zhang
A1 Zhaoyi Chen
A1 Yi Guo
A1 Thomas J George, Jr
A1 Yong Chen
A1 Fei Wang
A1 Jiang Bian
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.06.10.21258706.abstract
AB Recently, there is a growing interest in using real-world data (RWD) to generate real-world evidence (RWE) that complements clinical trials. Nevertheless, to quantify the treatment effects, it is important to develop meaningful RWD-based endpoints. In cancer trials, two real-world endpoints are particularly of interest: real-world overall survival (rwOS) and real-world time to next treatment (rwTTNT). In this work, we identified ways to calculate these real-world endpoints with structured EHR data, and validated these endpoints against the gold-standard measurements of these endpoints derived from linked EHR and TR data. In addition, we also examined and reported the data quality issues especially the inconsistency between the EHR and TR data. Using survival model, our result showed that patients (1) without subsequent chemotherapy or (2) with subsequent chemotherapy and longer rwTTNT, would have longer rwOS, showing the validity of using rwTTNT as a real-world surrogate marker for measuring cancer endpoints.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by NIH grants R01CA246418, R21AG068717, and R21CA245858 and the OneFlorida Clinical Research Consortium (CDRN-1501-26692) funded by PCORI. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or PCORI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Florida IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOneFlorida data can be requested at https://onefloridaconsortium.org/front-door/; Since OneFlorida data is a HIPAA limited data set, a data use agreement needs to be established with the OneFlorida network.